Significance of serum tissue inhibitor of metalloproteinases-1 in various liver diseases

Journal of Hepatology

Volumn 24, Issue 2, 1996, Pages 177-184

  Ueno, Takato ^a   Tamaki, Seishu ^a   Sugawara, Hiroshi ^a   Inuzuka, Sadataka ^a   Torimura, Takuji ^a   Sata, Michio ^a   Tanikawa, Kyuichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Fibrogenesis; Laminin P1; Liver diseases; Tissue inhibitor of metalloproteinases; Type III procollagen N peptide (P III P); Type IV collagen

Indexed keywords

COLLAGEN TYPE 4; LAMININ; METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; PROCOLLAGEN;

ALCOHOL LIVER DISEASE; ARTICLE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FIBROGENESIS; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0030023829     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(96)80027-4     Document Type: Article

References (51)

1. Arthur MJP. Matrix degradation in the liver. Semin Liver Dis 1990; 10: 47-55.
2. Emonard H, Grimaud JX. Matrix metalloproteinases. A review. Cell Mol Biol 1990; 36: 131-53.
3. Khokha R, Denhardt DT. Matrix metalloproteinases and tissue inhibitor of metalloproteinases: a review of their role in tumorigenesis and tissue invasion. Invasion Metastasis 1989; 9: 391-405.
4. Woessner JF, Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991; 5: 2145-54.
5. Chojkier M, Brenner DA. Therapeutic strategies for hepatic fibrosis. Hepatology 1988; 8: 176-82.
6. Davis BH. Hepatic fibrogenesis: new developments? Am J Gastroenterol 1987; 82: 544-6.
7. Torres-Salinas M, Pares A, Caballeria J, Jimenez W, Heredia D, Bruguera M, Rodes J. Serum procollagen type III peptide as a marker of hepatic fibrogenesis in alcoholic hepatitis. Gastroenterology 1986; 90: 1241-6.
8. Frei A, Zimmermann A, Weigand K. The N-terminal propeptide of collagen type III in serum reflects activity and degree of fibrosis in patients with chronic liver disease. Hepatology 1984; 4: 830-4.
9. Galambos MR, Collins DC, Galambos JT. A radioimmunoassay procedure for type III procollagen: its use in the detection of hepatic fibrosis. Hepatology 1985; 5: 38-42.
10. Schuppan D, Dumont JM, Kim KY, Hennings G, Hahn EG. Serum concentration of the aminoterminal procollagen type III peptide in the rat reflects early formation of connective tissue in experimental liver cirrhosis. J Hepatol 1986; 3: 27-37.
11. Bentsen KD, Horslev-Petersen K, Junker P, Juhl E, Lorenzen I, The Copenhagen hepatitis acute programme. Serum aminoterminal procollagen type III peptide in acute viral hepatitis. A long-term follow-up study. Liver 1987; 7: 96-105.
12. Chang TT, Lin HC, Lee SD, Tsai YT, Lee FY, Jeng FS, Wu JC, Yeh PSH, Lo KJ. Clinical significance of serum type III procollagen aminopropeptide in hepatic B virus-related liver diseases. Scand J Gastroenterol 1989; 24: 533-8.
13. Leblond-Francillard M, Augereau C, Nalpas B, Trinchet JC, Hartmann DJ, Berthelot P, Beaugrand M, Brechot C. Liver collagen mRNA and serum aminoterminal peptide of type III procollagen (P III NP) levels in patients with alcoholic liver disease. J Hepatol 1989; 9: 351-8.
14. Matsumoto E, Muragaki Y, Ooshima A. Increased amount of serum type IV collagen peptide in human liver fibrosis as determined by enzyme-immunoassay with monoclonal antibodies. Acta Pathol Jpn 1989; 39: 217-23.
15. Ueno T, Inuzuka S, Torimura T, Ohira H, Ko H, Obata K, Sata M, Yoshida H, Tanikawa K. Significance of serum type-IV collagen levels in various liver diseases. Measurement with a one-step sandwich enzyme immunoassay using monoclonal antibodies with specificity for pepsin-solubilized type-IV collagen. Scand J Gastroenterol 1992; 27: 513-20.
16. 1, procollagen-III peptides, and N-acetyl-β-glucosaminidase for monitoring the activity of liver fibrosis. Hepato-gastroenterol 1989; 36: 506-10.
17. Murawaki Y, Yamamoto H, Kawasaki K, Shima H. Serum tissue inhibitor of metalloproteinases in patients with chronic liver disease and with hepatocellular carcinoma. Clin Chim Acta 1993; 218: 47-58.
18. Muzzillo DA, Imoto M, Fukuda Y, Koyama Y, Saga S, Nagai Y, Hayakawa T. Clinical evaluation of serum tissue inhibitor of metalloproteinases-1 levels in patients with liver diseases. J Gastroenterol Hepatol 1993; 8: 437-41.
19. Murawaki Y, Ikuta Y, Koda M, Kawasaki H. Serum type III procollagen peptide, type IV collagen 7S domain, central triple-helix of type IV collagen and tissue inhibitor of metalloproteinases in patients with chronic viral liver disease: relationship to liver histology. Hepatology 1994; 20: 780-7.
20. Li J, Rosman AS, Leo MA, Nagai Y, Lieber CS. Tissue inhibitor of metalloproteinase is increased in the serum of precirrhotic and cirrhotic alcoholic patients and can serve as a marker of fibrosis. Hepatology 1994; 19: 1418-23.
21. Review by an international group. Acute and chronic hepatitis revisited. Lancet 1977; ii: 914-9.
22. Review by an international group. Alcoholic liver disease: morphological manifestations. Lancet 1981; i: 707-11.
23. Kodama S, Kishi J, Obata K, Iwata K, Hayakawa T. Monoclonal antibodies to bovine collagenase inhibitor. Collagen Rel Res 1987; 7: 341-50.
24. Kodama S, Yamashita K, Kishi J, Iwata K, Hayakawa T. A sandwich enzyme immunoassay for collagenase inhibitor using monoclonal antibodies. Matrix 1989; 9: 1-6.
25. Rohde H, Vargas L, Hahn E, Kalbfleisch H, Bruguera M, Timpl R. Radioimmunassay for type III procollagen peptide and its application to human liver disease. Eur J Clin Invest 1979; 9: 451-9.
26. Obata K, Iwata K, Ichida T, Inoue K, Matsumoto E, Muragaki Y, Ooshima A. One step sandwich enzyme immunoassay for human type IV collagen using monoclonal antibodies. Clin Chem Acta 1989; 181: 293-304.
27. Gabrielli GB, Corrocher R. Hepatic fibrosis and its serum markers: a review. Dig Dis 1991; 9: 303-316.
28. Colombo M, Annoni G, Donato MF, Conte D, Martines D, Zaramella MG, Bianti PA, Piperno A, Tiribelli C. Serum type III procollagen peptide in alcoholic liver disease and idiopathic hemochromatosis: its relationship to hepatic fibrosis, activity of the disease and iron overload. Hepatology 1985; 5: 475-9.
29. Kropf J, Gressner AM, Negwer A. Efficacy of serum laminin measurement for diagnosis of fibrotic liver diseases. Clin Chem 1988; 34: 2026-30.
30. Sakamoto S, Sakamoto M, Matsumoto A, Nagayama M, Glimcher MJ. Chick bone collagenase inhibitor and latency of collagenase. Biochem Biophys Res Commun 1981; 103: 339-46.
31. Kishi J, Hayakawa T. Purification and characterization of bovine dental pulp collagenase inhibitor. J Biochem 1984; 96: 395-404.
32. Macartney HW, Tscheshe M. The collagenase inhibitor from human polymorphonuclear leukocytes isolation, purification and characterization. Eur J Biochem 1983; 130: 79-83.
33. Otsuka K, Sodek J, Limeback H. Synthesis of collagenase and collagenase inhibitor by osteoblast like cells in culture. Eur J Biochem 1984; 145: 123-9.
34. Dean DD, Woessner JF. Extracts of human articular cartilage contain an inhibitor of tissue metalloproteinases. Biochem J 1984; 218: 277-80.
35. Welgus HG, Stricklin GP. Human skin fibroblast collagenase inhibitor. J Biol Chem 1983; 258: 12259-64.
36. Stricklin GP, Welgus HG. Human skin fibroblast collagenase inhibitor. J Biol Chem 1983; 258: 12252-8.
37. Welgus HG, Campbell EJ, Bar-Shavit Z, Senior RM, Teitelbaum SL. Human alveolar macrophages produce a fibroblast-like collagenase and collagenase inhibitor. J Clin Invest 1985; 76: 219-24.
38. Cooper TW, Eisen AZ, Stricklin GP, Welgus HG. Platelet-derived collagenase inhibitor: characterization and subcellular localization. Proc Natl Acad Sci USA 1985; 82: 2779-83.
39. Murray JB, Allison K, Sudhalter J, Langer R. Purification and partial amino acid sequence of a bovine cartilage-derived collagenase inhibitor. J Biol Chem 1986; 261: 4154-9.
40. Hembry RM, Murphy G, Reynords JJ. Immunolocalization of tissue inhibitor of metalloproteinases (TIMP) in human cells. J Cell Sci 1985; 73: 105-19.
41. Hoshino T, Kishi J, Kawai T, Kobayashi K, Hayakawa T. Immunoelectron microscopic localization of collagenase inhibitor in bovine dentin. Collagen Rel Res 1986; 6: 303-12.
42. Ito A, Sato T, Iga T, Mori Y. Tumor necrosis factor bifunctionally regulates matrix metalloproteinases and tissue inhibitor of metalloproteinases (TIMP) production by human fibroblasts. FEBS 1990; 269: 93-5.
43. DeClerck YA, Yean TD, Chan D, Shimada H, Langley KE. Inhibition of tumor invasion of smooth muscle cell changes by recombinant human metalloproteinase inhibitor. Cancer Res 1991; 51: 2151-7.
44. Iredale JP, Murphy G, Hembry RM, Friedman SL, Arthur MJP. Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinases-1. J Clin Invest 1992; 90: 282-7.
45. Roeb E, Graeve L, Hoffmann R, Decker K, Edwards DR, Heinrich PC. Regulation of tissue inhibitor of metalloproteinase-1 gene expression by cytokines and dexamethasone in rat hepatocyte primary cultures. Hepatology 1993; 18: 1437-42.
46. Kordula T, Güttgemann I, Rose-John S, Roeb E, Osthues A, Tschesche H, Koj A, Heinrich PC, Graeve L. Synthesis of tissue inhibitor of metalloproteinase-1 (TIMP) in human hepatoma cells (Hep G2). FEBS 1992; 313: 143-7.
47. Arthur MJP, Friedman SL, Ross J, Bissell DM. Lipocytes from normal rat liver release a natural metalloproteinase that degrades basement membrane (Type IV) collagen. J Clin Invest 1989; 84: 1076-85.
48. Li J, Kim C, Leo MA, Rojikind M, Leiber CS. Polyunsaturated lecithin prevents acetaldehyde-mediated hepatic collagen accumulation by stimulating collagenase activity in cultured lipocytes. Hepatology 1992; 15: 373-81.
49. Murphy G, Reynolds JJ, Werb Z. Biosynthesis of tissue inhibitor of metalloproteinases by human fibroblasts in culture. J Biol Chem 1985; 260: 3079-83.
50. Carmichael DF, Sommer A, Thompson RC, Anderson DC, Smith CG, Welgus HG, Stricklin GP. Primary structure and cDNA cloning of human fibroblast collagenase inhibitor. Proc Natl Acad Sci USA 1986; 83: 2407-11.
51. Lambert CA, Soudant EP, Nusgens BV, Lapiere CM. Pretransitional regulation of extracellular matrix macromolecules and collagenase expression in fibroblasts by mechanical forces. Lab Invest 1992; 66: 444-51.